XML 51 R34.htm IDEA: XBRL DOCUMENT
v3.22.4

SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details) |  |  | 1 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | ---
Jul. 02, 2021 USD ($) $ / shares | May 13, 2021 USD ($) | Jul. 23, 2018 USD ($) | Oct. 19, 2017 USD ($) | Oct. 31, 2015 | Dec. 31, 2022 USD ($) item $ / shares shares | Dec. 31, 2021 USD ($) $ / shares shares | Dec. 31, 2020 shares | Jun. 30, 2021 USD ($) | Dec. 01, 2016
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares |  |  |  |  |  | $ 0.001 | $ 0.001 |  |  |
Accounts receivable - Trade |  |  |  |  |  | $ 4,586,000 | $ 3,442,000 |  |  |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares |  |  |  |  |  | 34,097,716 | 28,502,017 | 22,850,682 |  |
Fiocruz |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Accounts receivable - Trade |  |  |  |  |  | $ 2,300,000 |  |  |  |
Chiesi |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Accounts receivable - Trade |  |  |  |  |  | 1,200,000 |  |  |  |
Pfizer |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Accounts receivable - Trade |  |  |  |  |  | 1,100,000 |  |  |  |
2021 Notes |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Aggregate principal amount |  |  |  |  |  | $ 0 | $ 0 |  |  |
Interest rate (as a percent) |  |  |  |  |  | 7.50% |  |  |  | 7.50%
2024 Notes |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Aggregate principal amount |  |  |  |  |  | $ 28,750,000 |  |  |  |
Interest rate (as a percent) |  |  |  |  |  | 7.50% |  |  |  |
Minimum cash balance required |  |  |  |  |  | $ 7,500,000 |  |  |  |
Minimum |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Tax Rate Assumption Related To Deferred Tax Difference Reversal |  |  |  |  |  | 23.00% |  |  |  |
Maximum |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Tax Rate Assumption Related To Deferred Tax Difference Reversal |  |  |  |  |  | 21.00% |  |  |  |
Amended Pfizer Agreement | Protalix Bio Therapeutics Incorporation | Brazil |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement Revenues Expenses Sharing Percentage |  |  |  |  | 100.00% |  |  |  |  |
Chiesi US Agreement and Chiesi Ex-US Agreement |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Non-refundable Payment Receivable |  |  | $ 25,000,000.0 | $ 25,000,000.0 |  | $ 50,000,000.0 |  |  |  |
Agreement Amendment Payment Receivable |  |  |  |  |  | $ 10,000,000.0 |  |  | $ 10,000,000.0 |
Performance obligation number | item |  |  |  |  |  | 2 |  |  |  |
Chiesi US Agreement |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Non-refundable Payment Receivable |  |  | 25,000,000.0 |  |  |  |  |  |  |
Additional Amounts Payable To Cover Development Costs |  |  | 20,000,000.0 |  |  |  |  |  |  |
Additional amount payable for achievement of regulatory and commercial milestones |  |  | $ 760,000,000.0 |  |  | $ 735,000,000.0 |  |  |  |
Chiesi US Agreement | Minimum |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Payment On Net Sales Percentage |  |  | 15.00% |  |  | 15.00% |  |  |  |
Chiesi US Agreement | Maximum |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Payment On Net Sales Percentage |  |  | 40.00% |  |  | 40.00% |  |  |  |
Chiesi Ex-US Agreement |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Non-refundable Payment Receivable |  |  |  | 25,000,000.0 |  |  |  |  |  |
Additional Amounts Payable To Cover Development Costs |  |  |  | 25,000,000.0 |  |  |  |  |  |
Additional amount payable for achievement of regulatory and commercial milestones |  |  |  | $ 320,000,000.0 |  |  |  |  |  |
Change in amount receivable for achievement of regulatory and commercial milestones |  | $ 25,000,000.0 |  |  |  |  |  |  |  |
Agreement Amendment Payment Receivable |  | $ 10,000,000.0 |  |  |  |  |  |  |  |
Chiesi Ex-US Agreement | Minimum |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Payment On Net Sales Percentage |  |  |  | 15.00% |  | 15.00% |  |  |  |
Chiesi Ex-US Agreement | Maximum |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Payment On Net Sales Percentage |  |  |  | 35.00% |  | 35.00% |  |  |  |
ATM Shares |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.001 |  |  |  |  |  |  |  |  |
Sale of stock, maximum offering price | $ 20,000,000.0 |  |  |  |  | $ 11,300,000 |  |  |  |

X
- Definition The total amount payable to entity for the achievement of regulatory and commercial milestones. + References No definition available. + Details
Name: | plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount payable to the entity to cover development costs under agreement. + References No definition available. + Details
Name: | plx_AdditionalAmountsPayableToCoverDevelopmentCosts
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Agreement Amendment Payment Receivable + References No definition available. + Details
Name: | plx_AgreementAmendmentPaymentReceivable
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones + References No definition available. + Details
Name: | plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative arrangement revenues and expense sharing percentage. + References No definition available. + Details
Name: | plx_CollaborativeArrangementRevenuesExpensesSharingPercentage
Namespace Prefix: | plx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Minimum cash balance required to be maintained under long term debt agreements. + References No definition available. + Details
Name: | plx_MaintainOfMinimumCashBalance
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the payment as a percentage of future net sales. + References No definition available. + Details
Name: | plx_PaymentOnNetSalesPercentage
Namespace Prefix: | plx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue, Performance Obligation, Number + References No definition available. + Details
Name: | plx_RevenuePerformanceObligationNumber
Namespace Prefix: | plx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Sale of stock, maximum offering price. + References No definition available. + Details
Name: | plx_SaleOfStockMaximumOfferingPrice
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | plx_SignificantAccountingPoliciesLineItems
Namespace Prefix: | plx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Deferred taxes are computed using the tax rates expected to be in effect when those differences reverse. + References No definition available. + Details
Name: | plx_TaxRateAssumptionRelatedToDeferredTaxDifferenceReversal
Namespace Prefix: | plx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights. + References No definition available. + Details
Name: | plx_UpfrontNonrefundableNoncreditablePaymentReceivable
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 45 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522 + Details
Name: | us-gaap_AccountsReceivableNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 + Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Face amount or stated value per share of common stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)) -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878 + Details
Name: | us-gaap_ConvertibleDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contractual interest rate for funds borrowed, under the debt agreement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 1B -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_DebtInstrumentInterestRateStatedPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | srt_MajorCustomersAxis=plx_FiocruzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=plx_ChiesiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=plx_PfizerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_BR
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |